No Data
No Data
Roth MKM Maintains Buy on Panbela Therapeutics, Maintains $25 Price Target
Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.
Earnings Call Summary | Panbela Therapeutics(PBLA.US) Q4 2023 Earnings Conference
The following is a summary of the Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript:Financial Performance:Panbela's general and administrative expenses were down to $0.9 million due t
Press Release: Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Panbela Therapeutics, Inc. (NASDAQ:PBLA) today provides a business update and reports financial results for the quarter and full year ended December 31, 2023.
Recap: Panbela Therapeutics Q4 Earnings
Panbela Therapeutics (OTC:PBLA) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:10 PM.Here's what investors need to know about the announcement.EarningsPanbela Therapeutics missed es
Panbela Therapeutics GAAP EPS of -$65.90 Beats by $151.10
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Panbela Therapeutics, Inc. (NASDAQ:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
No Data